Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a ...

Spravato is approved as an adjunctive therapy administered by a nasal spray and is based on esketamine, a form of the drug ketamine, an anaesthetic commonly used illegally for recreational purposes.

The United States Food and Drug Administration (FDA) has approved Spravato (esketamine), a nasal spray from Johnson & Johnson, as a stand-alone therapy for adults with major depressive disorder ...

A drug inspired by the anesthetic ketamine just became the first new kind of depression medication in 35 years. Called Spravato, a brand name for esketamine, and developed by Johnson & Johnson ...

Medicare does not currently provide coverage for ketamine therapy or infusions to treat mental health conditions. This is because the Food and Drug Administration (FDA) only approves the drug ...